Arena Pharmaceuticals Inc (ARNA.OQ)
Tue, Nov 7 2017
* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results
* Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results
* Arena Pharmaceuticals announces pricing of public offering of common stock
* Arena Pharmaceuticals announces proposed public offering of common stock
U.S. drug developer Arena Pharmaceuticals Inc said on Monday its experimental drug for pulmonary arterial hypertension (PAH), a rare but deadly lung disease, met the main goal in a mid-stage study.
BRIEF-Arena Pharmaceuticals Inc's board increased size of board from nine directors to ten directors
* Arena Pharmaceuticals Inc - on June 13, 2017, board of directors increased size of board from nine directors to ten directors Source text:(http://bit.ly/2rAYXbA) Further company coverage:
* Arena Pharmaceuticals announces shareholders and board of directors approve reverse stock split
- Arena Q3: Loss But Progress On Pipeline
- Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
- Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2017 Results - Earnings Call Transcript
- Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi
- The Small Cap Rush!
- Biotech Analysis Central Launched: Exclusive Research From Terry Chrisomalis